Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

142results about How to "Low friability" patented technology

Quick-disintegrating tablet in buccal cavity and manufacturing method thereof

The present invention relates to a quick-disintegrating tablet in the buccal cavity comprising a drug, a diluent, and a saccharide with a relatively lower melting point than the drug and the diluent, which is obtained by uniformly mixing the saccharide with a low melting point in the tablet so that a bridge will be formed between said drug and/or said diluent particles by the product of melting and then solidification of this saccharide with a low melting point. Moreover, the present invention relates to a method of manufacturing a quick-disintegrating tablet in the buccal cavity comprising a drug, a diluent and a saccharide with a relatively lower melting point than the drug and the diluent, which comprises (a) the process whereby tablet starting materials including a drug, a diluent, and a saccharide with a relatively lower melting point than the drug and the diluent are molded under the low pressure necessary for retaining the shape of a tablet, (b) the process whereby the molded product obtained in process (a) is heated to at least the temperature at which this saccharide with a low melting point will melt, and (c) the process whereby the molded product obtained in process (b) is cooled to at least the temperature at which the molten saccharide with a low melting point solidifies. The present invention presents a quick-disintegrating tablet in the buccal cavity that can be used for practical purposes in that it has almost the same properties as conventional oral pharmaceutical tablets, that is, it has sufficient tablet strength that it can be used with automatic unit dosing machines, and it is produced by conventional tableting machines, and a manufacturing method thereof. Moreover, the present invention presents a quick-disintegrating tablet in the buccal cavity which, in comparison to conventional quick-disintegrating tablets in the buccal cavity, has increased tablet strength and an improved friability without prolonging the disintegration time in the buccal cavity, and a manufacturing method thereof.
Owner:ASTELLAS PHARMA INC

Hollow capsule and preparation method thereof

The invention discloses a hollow capsule, which comprises the following components in parts by weight: 10 to 30 parts of kappa-carrageenan, 90 to 180 parts of water-soluble crosslinked starch, and 20 to 40 parts of plasticizer. The invention also discloses a preparation of the hollow capsule, which comprises the following steps of: 1) dissolving gum, wherein carrageenan and water-soluble crosslinked starch are stirred, water at a temperature of between 70 and 90 DEG C is added into the mixture, the plasticizer in the amount of the prescription is added and completely dissolved, and the mixture is stirred uniformly; 2) culturing the gum, wherein the gum liquid obtained in the step 1) is cooled to a temperature of between 40 and 45 DEG C, the gum liquid is insulated and stood for 30 to 60 minutes, and the gum liquid is put into a gum soaking tank; and 3) soaking the gum, wherein when the temperature of the gum liquid in the gum soaking tank is cooled to 35 DEG C, operations of gum soaking, drying, shell pulling out, cutting and buckling are automatically carried out through a capsule template. According to the hollow capsule disclosed by the invention, the transparency and toughness are remarkably improved, the friability is remarkably reduced, and the product yield is greatly increased.
Owner:青岛晓丛生物科技有限公司

Lelrozol tablet and preparation method thereof

The invention belongs to the technical field of medicine and particularly relates to a lelrozol tablet and a preparation method thereof. The lelrozol tablet is prepared from lelrozol and silicified microcrystalline cellulose, wherein the content of the silicified microcrystalline cellulose accounts for 20 to 60 percent of total weight of the tablets. The particle size D(v, 0.9) of the lelrozol issmaller than or equal to 60mu m, preferably the particle size D(v, 0.9) of the lelrozol is smaller than or equal to 40mu m and more preferably, the particle size D (v, 0.9) of the lelrozol is smallerthan or equal to 8mu m. According to the preparation method of the lelrozol tablet, disclosed by the invention, the silica microcrystalline cellulose is used, so that the trazodone is uniformly dispersed in the mixed powder; in addition, the lelrozol tablet has good fluidity, and the powder can be directly pressured into tablets, so that the technique is simplified, the time is saved and the laborintensity is low; besides, after a crude drug is crushed, the particle size is obviously reduced; by controlling the content of a disintegrating agent, the dissolution rate of the prepared lelrozol tablet is significantly increased, 85 percent or above can be reached in 15 minutes and thereby the lelrozol tablet is rapidly dissolved out.
Owner:HAINAN JINRUI PHARMA CO LTD

Sarpogrelate hydrochloride sustained release pellet and preparation method thereof

The invention belongs to the field of medicinal preparation and discloses a sarpogrelate hydrochloride sustained release pellet and a preparation method thereof. The pellet is prepared by coating a sustained release coat on a medicine contained pellet core, wherein the formula of the medicine contained pellet core comprises the following raw materials in parts by weight: 75-100 parts of sarpogrelate hydrochloride and 0-25 parts of excipient, wherein the total weight part of the sarpogrelate hydrochloride and the excipient is 100 or the weight parts of the sarpogrelate hydrochloride and the excipient are increased or reduced by the same ratio; a surfactant accounts for 0.1-8% of the total weight of the sarpogrelate hydrochloride and the excipient; and a wetting agent accounts for 0.1-30% of the total weight of the sarpogrelate hydrochloride and the excipient. By using the preparation method disclosed by the invention, the medicine contained pellet core with low friability, higher yield, smaller particle size and smooth surface can be obtained; the pellet core is convenient to be further processed; according to the invention, the medicine contained pellet core is coated with the sustained release coat so as to obtain a potassium citrate sustained release pellet; and the pellet has the advantages of controllable and stable quality in vitro and sustained release characteristics in vivo.
Owner:JINLING PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products